Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
clinical trial data
Biotech
Sanofi $110M radioligand therapy hits main goal in ph. 2 trial
Sanofi’s bet on a radioligand therapy seems to be paying off after the neuroendocrine tumor treatment hit the key endpoints of a phase 2 study.
James Waldron
Oct 8, 2025 6:25am
Skye's CB1 blocker fails to reduce weight in obesity study
Oct 6, 2025 7:55am
Pfizer’s new prize Metsera touts 14% weight loss for GLP-1
Sep 30, 2025 6:40am
Enanta sees RSV drug fail phase 2b but finds positives
Sep 29, 2025 8:05am
Harmony's pivotal trial flops as placebo response causes discord
Sep 24, 2025 9:35am
BMS reports phase 3 win in multiple myeloma
Sep 23, 2025 8:20am
